Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape

The programme is designed to offer an overview of research in this area and review the current status and future prospects of immunotherapy in HNSCC.

Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape
Live from ESMO Congress 2019
Chair: Anthony TC Chan
Monday 30 September – 16.00 CET

Register now

Welcome to the ESMO Webinar om Immune Checkpoint Inhibitors in HNSCC

chan-anthony no bg

It is with great pleasure that I invite you to participate in the ESMO Webinar entitled ‘Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape’.  The webinar will be broadcast at 16:00 CET on 30 September from ESMO 2019 Congress in Barcelona.
  
Until recently there were limited treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) when they progress on systemic chemotherapy.
  
However, immunotherapy is now an important option in that setting. Furthermore, positive data in first-line setting have recently emerged. Therefore, it is very important to continue research efforts to address questions on how best to incorporate these agents and move them earlier in clinical care of patients with HNSCC, along with optimising selection criteria for the treatment with immune checkpoint inhibitors.
  
I am delighted to announce the lectures by three distinguished experts in the field who will join me in this webinar.
During the webinar, we’ll cover topics such as a current place of immune checkpoint inhibitors in the management of patients with recurrent/metastatic HNSCC, role of biomarkers for selecting patients for immunotherapy, and research efforts on immunotherapy in the curative HNSCC setting. We will discuss various aspects of the potential and advantages of immune checkpoint inhibitors over conventional treatment modalities for HNSCC and prospects of their combinations.
  
The programme is designed to offer an overview of research in this area and review the current status and future prospects of immunotherapy in HNSCC.
  
I encourage you to join us in this stimulating new ESMO activity.

Anthony TC Chan
Department of Clinical Oncology The Chinese University of Hong Kong, China

Register now

Programme

  • Welcome and Introduction, Anthony TC Chan, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China
  • IO in the Management of Recurrent/Metastatic HNSCC, Jean-Pascal Machiels, Cliniques universitaires Saint-Luc, Université catholique de Louvain Brussels, Belgium
  • Biomarkers for IO in HNSCC, Amanda Psyrri, National Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
  • Immunotherapy in the Curative HNSCC Setting, Ezra Cohen, UC San Diego Health, Moores Cancer Center, San Diego, USA
  • Q&A and Closing Remarks, Anthony TC Chan, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

Learning objectives

  • To understand the current evidence on treatment with immune checkpoint inhibitors in the recurrent/metastatic HNSCC 
  • To discuss the role of biomarkers in selection of the patients with HNSCC who might benefit from the treatment with immune checkpoint inhibitors 
  • To provide an update on ongoing clinical investigations and future outlook in terms of IO in the curative HNSCC setting 

Faculty

Name Photo Affiliation
Anthony TC Chan
chan-anthony no bg
Department of Clinical Oncology, The Chinese University of Hong Kong
Hong Kong, China
Ezra Cohen
cohen-ezra no bg
UC San Diego Health, Moores Cancer Center
San Diego, USA
Jean-Pascal Machiels
machiels-jean-pascal no bg
Cliniques universitaires Saint-Luc, Université catholique de Louvain
Brussels, Belgium
Amanda Psyrri
psyrri-amanda no bg
National Kapodistrian University of Athens, Attikon Hospital
Athens, Greece

Register now

*This content is only available to ESMO members. Find out more about becoming a member.